Bio-Kult Infantis® in AAD Prevention in Infants

Efficacy of a Synbiotic Product (Probiotics + Prebiotics) in the Prevention of Antibiotics-associated Diarrhoea (AAD) in Infants. A Multicenter, Double Blind, Parallel Group, Placebo Controlled, Randomized Study

Background: antibiotic-associated diarrhoea (AAD) is defined as an acute inflammation of the intestinal mucosa associated to the administration of antibiotics. Its aetiology seems to be linked to the impact of antibiotics on the normal digestive microbiota. Acute otitis media (AOM) is a common paediatric condition and it is one of the most commonly cited indication for antimicrobial therapy in children (amoxicillin + clavulanic acid).

Treatment modalities for AAD are limited because no established treatment exists for non-Clostridium difficile associated AAD, except for discontinuing antibiotic therapy. Measures to prevent AAD include the use of probiotics. The rationale for the use of probiotics in AAD assumes that, considering the pathogenesis of AAD, AAD is associated with disturbance in the normal intestinal microbiota; administrating specific probiotic strains it is possible to normalize unbalanced indigenous microbiota.

Scientific evidence suggests that prebiotics could be beneficial too. Prebiotics can act in synergy with probiotics, being efficacious in suppressing the growth of pathogenic bacteria that may occur during antibiotic therapy.

Study rationale: the principal side effects of treatment with amoxicillin-clavulanate include diarrhoea, vomiting and allergic reactions. Aim of this study is to evaluate the effectiveness of the administration of a synbiotic product, Bio-Kult Infantis®, in the prevention of AAD during a standard therapy with amoxicillin-clavulanate to treat AOM.

Objective: to evaluate the effectiveness of a synbiotic product in the prevention of Antibiotics-Associated Diarrhoea (AAD) during a concomitant standard therapy with amoxicillin / clavulanic acid, also known as co-amoxiclav, to treat Acute Otitis Media (AOM).

Study design: this is a multicenter, double blind, parallel group, placebo controlled, randomized clinical study. 276 children 6 - 35 months old will be enrolled and then randomized into one of the two study groups (Bio-Kult Infantis® + co-amoxiclav standard treatment for AOM / placebo + co-amoxiclav standard treatment for AOM). A comparison will be performed to evaluate the effectiveness of a synbiotic product in the prevention of AAD during the concomitant standard therapy with co-amoxiclav.

During the study 4 visits will have to be performed at the study centre, and extra visits will be performed in case of AOM relapse after recovery. The study will last for each patient 38 ± 6 days.

Study Overview

• Status: Unknown
• Conditions: Acute Otitis Media
• Intervention / Treatment: Dietary supplement: Biokult; Dietary supplement: Placebo

• Study Type: Interventional
• Enrollment (Anticipated): 276
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Ashton Harper, Dr.; Phone Number: +44 7712 321 033; Email: Ashton.Harper@protexin.com
• Study Contact Backup: Name: Cesare Mutti, Dr; Phone Number: +390245495838; Email: cesare.mutti@sprim.com

Study Locations

• Italy
  • Italia
    • Roma, Italia, Italy, 00157
      • Recruiting
      • Hospital "Sandro Pertini"
      • Contact: Salvatore Tripodi, Dr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 months to 2 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• 1. Parents / legal guardians signed written informed consent to participate in the study.
• 2. Male and female infants aged 6 - 35 months (6 and 35 inclusive).
• 3. Infants eligible to receive co-amoxiclav to treat AOM according to current Italian guidelines, edited by Società Italiana di Pediatria, 2012.
• 4. Outpatients infants (not hospitalized).
• 5. Infants who have received at least 2 doses of pneumococcal conjugate vaccine.

• 6. Infants diagnosed with Acute Otitis Media (AOM) based on the following three criteria:

  1. onset, within the preceding 48 hours, of symptoms that parents or legal guardians rated with a score of at least 3 on the Acute Otitis Media Severity of Symptoms (AOM - SOS);
  2. presence of middle-ear effusion;
  3. moderate or marked bulging of the tympanic membrane or slight bulging accompanied by either otalgia or marked erythema of the membrane
• 7. Infants already exposed to formula milk without Cow Milk Protein Allergy (CMPA) (not requiring a formal diagnosis of CMPA).

Exclusion Criteria:

• 1. Infants with any other acute illness apart from AOM (e.g. pneumonia) or with any other chronic illness (e.g. cystic fibrosis).
• 2. Infants with a clinical history positive for any allergy or intolerance to amoxicillin, clavulanic acid or any component of the active product, the placebo or of the rescue medication (acetaminophen).
• 3. Infants presenting contraindications to the study products, to co-amoxiclav or to the rescue medication, according to concerning Summaries of Product Characteristics (SPC).
• 4. Infants being treated with any drug whose pharmacokinetics can interfere with the intake of amoxicillin, clavulanic acid, the study products or the rescue medication or with any drug with which amoxicillin, clavulanic acid, the study products or the rescue medication can interact, according to concerning Summaries of Product Characteristics (SPC).
• 5. Infants with a clinical history positive for allergy to any other antibiotics.
• 6. Infants who have received antibiotics within 8 weeks prior to enrollment.
• 7. Infants who have had otalgia for longer than 48 hours or perforation of the tympanic membrane.
• 8. Infants suffering from active diarrhoea at time of enrollment or chronic diarrhoea.
• 9. Infants who consumed a probiotic product for medicinal purposes within 7 days prior to enrollment.
• 10. Unwillingness on the part of the parents or legal guardians to interrupt any regular intake of other probiotics during the study period
• 11. Diagnosis of Clostridium difficile-associated diarrhoea (CDAD) within the previous three months from enrolment

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Bio-Kult Infantis; 1 sachet once a day mixed with milk, water or food.	Dietary supplement: Biokult; Bio-Kult Infantis® is a multi-strain formula containing a probiotic formulation comprising 7 strains of probiotics, high content of Omega-3, Vitamin D3 and Preplex® (50% FOS and 50% gum acacia). Each sachet contains: Minimum 1 billion microorganisms per sachet (1 x 109CFU/g), guaranteed throughout the shelf life; DHA + EPA: >1mg per sachet; Vitamin D3: 2.5mcg per sachet (50% of Nutrient Reference Value). Bio-Kult Infantis® presents itself in the form of a white powder, packaged in sachets of 1 g each
Placebo Comparator: Placebo; 1 sachet once a day mixed with milk, water or food.	Dietary supplement: Placebo; IP placebo is manufactured so to contain maltodextrin DE19 and have the same organoleptic properties of the active product (similar to the study product in appearance and taste) but without active ingredient. It contains 100% maltodextrin DE19. Moreover, placebo sachets are equal in color, shape and weight (1 g) to IP sachets.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of AAD	occurrence or non-occurrence of AAD according to time frame. An occurrence of AAD is defined as 3 or more watery stools in 1 day or 2 watery stools daily for at least 2 days	day 10

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of AAD	occurrence or non-occurrence of AAD according to time frame	Days 24 and 38
Duration of AAD	Frequency (frequency of the occurrences as mean) of AAD according to time frame	Days 10, 24 and 38
Mean stool consistency during antibiotic treatment	Stool consistency evaluated according to the validated Infatl Stool Scale; mean values will be considered according to time frame	from end of antibiotic treatment to Day 2, and from Day 24 to Day 38
Mean stool frequency	Frequency of evacuations (frequency of the occurrences per 24 hours)	Days 10, 24 and 38
Incidence and mean frequency of abdominal pain, nausea, vomiting, bloating, and appetite suppression	Occurrence or non-occurrence and frequency of occurrences as mean according to time frame	Days 10, 24 and 38
Time to resolution of AOM	Time (Days) to the first recording of an Acute Otitis Media Severity of Symptoms score (AOM-SOS Score) of 0 and 1 and the time to the second of two successive recordings of that score according to time frame	Day 38
Rate of resolution of AOM	frequency of occurrences (resolution of AOM) as mean according to time frame	Days 10, 24 and 38
Rate of residual middle-ear effusion (fluid behind the tympanic membrane)	frequency of occurrences (residual middle-ear effusion) as mean according to time frame	Days 10, 24 and 38
Rate of AOM relapse	frequency of occurrences (AOM relapse) as mean according to time frame	Days 24 and 38
Dermatitis in the diaper area (diaper rash)	occurrence / or non-occurrence of dermatitis according to time frame	Days 10, 24 and 38
Rate of interruption of antibiotic therapy	occurrence / or non-occurrence according to time frame	Day 10
Use of acetaminophen (as rescue medication)	Use of acetaminophen according to time frame	Day 38
Evaluation of product palatability	palatability valuated by parents / legal guardians by means of a VAS according to time frame	Day 24

Collaborators and Investigators

• Sponsor: Probiotics International Ltd.
• Collaborators: Sprim Advanced Life Sciences
• Investigators: Principal Investigator: Salvatore Tripodi, Dr, UOC pediatria Hospital "Sandro Pertini"

Study record dates

Study Major Dates

• Study Start (Actual): April 18, 2018
• Primary Completion (Anticipated): December 15, 2018
• Study Completion (Anticipated): December 15, 2018

Study Registration Dates

• First Submitted: April 19, 2018
• First Submitted That Met QC Criteria: May 3, 2018
• First Posted (Actual): May 4, 2018

Study Record Updates

• Last Update Posted (Actual): September 12, 2018
• Last Update Submitted That Met QC Criteria: September 11, 2018
• Last Verified: September 1, 2018

More Information

Terms related to this study

• Keywords: probiotics; prebiotics; diarrhoea
• Additional Relevant MeSH Terms: Otorhinolaryngologic Diseases; Ear Diseases; Otitis; Otitis Media
• Other Study ID Numbers: AAD_BKI_001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No